Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.74
    +0.26 (+0.33%)
     

  • GOLD FUTURES

    2,323.50
    -7.70 (-0.33%)
     

  • DOW

    38,878.15
    +25.88 (+0.07%)
     

  • Bitcoin GBP

    50,657.52
    +108.56 (+0.21%)
     

  • CMC Crypto 200

    1,315.20
    -49.92 (-3.66%)
     

  • NASDAQ Composite

    16,344.07
    -5.18 (-0.03%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BUZZ-Western pharma losing ground to local firms in China

Reuters - UK Focus

** Multinational drugmakers are losing share to local market players in China, notably in areas such as insulin, according to an analysis of IMS Health (NYSE: IMS - news) data by Barclays (LSE: BARC.L - news)

** Growth of the Chinese pharma market has slowed from 15% in 2013 to 6% in the second quarter of 2015, leading to disappointing results in the country for several Western companies

** Barclays says the pharma franchises of Merck KGaA (Other OTC: MKGAF - news) , UCB, Sanofi (NasdaqGM: GCVRZ - news) and Novartis are arguably the most resilient

** Relative slowdown in growth appears to have been greatest for AstraZeneca (NYSE: AZN - news) , Bristol-Myers Squibb, Eli Lilly and Ipsen (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)